Accessibility Menu
IDEAYA Biosciences logo

IDEAYA Biosciences

(NASDAQ) IDYA

Current Price$36.66
Market Cap$3.32B
Since IPO (2019)+212%
5 Year+61%
1 Year+63%
1 Month+20%

IDEAYA Biosciences Financials at a Glance

Market Cap

$3.32B

Revenue (TTM)

$225.27M

Net Income (TTM)

-$140.06M

EPS (TTM)

-$1.60

P/E Ratio

-21.85

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$36.66

Volume

327,927.939

Open

$35.47

Previous Close

$34.91

Daily Range

$35.11 - $36.72

52-Week Range

$20.50 - $39.28

Estimated Earnings Date

Aug 11, 2026

IDYA: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IDEAYA Biosciences

Industry

Biotechnology

Employees

145

CEO

Yujiro S. Hata, MBA

Headquarters

South San Francisco, CA 94080, US

IDYA Financials

Key Financial Metrics (TTM)

Gross Margin

29.70%

Operating Margin

-81.44%

Net Income Margin

-62.17%

Return on Equity

-13.96%

Return on Capital

-15.16%

Return on Assets

-13.59%

Earnings Yield

-4.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.32B

Shares Outstanding

95.08M

Volume

327.93K

Avg. Volume

1.27M

Financials (TTM)

Gross Profit

$66.91M

Operating Income

-$183.47M

EBITDA

-$135.46M

Operating Cash Flow

-$85.93M

Capital Expenditure

-$2.01M

Free Cash Flow

-$87.93M

Cash & ST Invst.

$671.20M

Total Debt

$28.60M

IDEAYA Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.56M

N/A

Gross Profit

$5.42M

+107.6%

Gross Margin

82.58%

N/A

Market Cap

$3.32B

N/A

Market Cap/Employee

$25.34M

N/A

Employees

131

N/A

Net Income

-$98.54M

-38.0%

EBITDA

-$97.40M

-38.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$671.20M

-3.1%

Total Debt

$28.60M

+10.1%

Accounts Receivable

$6.56M

N/A

Inventory

$0.00

N/A

Long Term Debt

$28.25M

+10.1%

Short Term Debt

$350.00K

+13.6%

Return on Assets

-13.59%

N/A

Return on Invested Capital

-19.00%

N/A

Free Cash Flow

-$76.14M

-23.5%

Operating Cash Flow

-$75.17M

-24.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADPTAdaptive Biotechnologies Corporation
$18.76+8.86%
BEAMBeam Therapeutics Inc.
$35.39+6.61%
FOLDAmicus Therapeutics, Inc.
$14.49+0.00%
KNSAKiniksa Pharmaceuticals International, plc
$60.66+1.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$8.03+0.28%
KEELKeel Infrastructure
$6.12-0.07%
EHGOEshallgo
$5.01+0.25%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$39.84-0.00%

Questions About IDYA

What is the current price of IDEAYA Biosciences?

IDEAYA Biosciences is trading at $36.50 per share.

What is the 52-week range for IDEAYA Biosciences?

Over the past 52 weeks, IDEAYA Biosciences has traded between $20.50 and $39.28.

How much debt does IDEAYA Biosciences have?

As of the most recent reporting period, IDEAYA Biosciences reported total debt of $28.60M.

How much cash does IDEAYA Biosciences have on hand?

IDEAYA Biosciences reported $157.52M in cash and cash equivalents in its most recent financial results.

What is IDEAYA Biosciences’s dividend yield?

IDEAYA Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.